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TRANSLATIONAL RELEVANCE 
 
The prognosis of patients afflicted by malignant glioma remains poor despite multimodal 
therapy. Therefore, there is an urgent need to dissect the cell-biological mechanisms that 
contribute to the malignant phenotype. Here, we demonstrate that gliomas express growth 
and differentation factor (GDF)-15 in vitro and in vivo. We provide evidence that GDF-15 
contributes to proliferation and immune escape of glioma cells. Most importantly, we show 
that silencing of glioma-derived GDF-15 leads to prolonged survival in syngeneic mice. 
Consequently, we propose GDF-15 as a novel target for future therapeutic approaches 
against malignant gliomas.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research. 
on March 14, 2014. © 2010 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 9, 2010; DOI: 10.1158/1078-0432.CCR-10-0705 
 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.  
Copyright © 2010  American Association for Cancer Research 
 
 
3
 
 
ABSTRACT 
 
Purpose: Growth and differentiation factor (GDF)-15 is a member of the transforming 
growth factor (TGF)-β family. GDF-15 is necessary for the maintenance of pregnancy but 
has also been linked to other physiological and pathological conditions.  
Experimental Design: The expression of GDF-15 in glioma cell lines was assessed by qRT-
PCR and immunoblot. GDF-15 levels in situ and in peripheral blood of glioma patients were 
examined by immunohistochemistry and ELISA, respectively. Effects of shRNA-mediated 
GDF-15 inhibition on proliferation and immunogenicity of SMA-560 glioma cells were 
investigated by [methyl-3H]thymidine incorporation and immune-mediated target cell lysis. 
The impact of GDF-15 on glioma growth in vivo was assessed in syngeneic mice. 
Results: GDF-15 is expressed by gliomas of different WHO grades as assessed by 
immunohistochemistry. The high expression of GDF-15 in tumor tissue translates into 
elevated GDF-15 serum levels in glioblastoma patients compared to healthy controls.  GDF-
15 mRNA and protein are also detectable in human and mouse glioma cells in vitro. 
Silencing of GDF-15 by RNA interference reduces the proliferation of malignant glioma 
cells. Immunologically, the depletion of glioma-derived GDF-15 enhances the susceptibility 
of mouse glioma cells towards syngeneic NK cells and splenocytes. This results into a 
reduced in vivo tumorigenicity and increased T cell infiltration of GDF-15-deficient glioma 
cells in syngeneic mice.  
Conclusions: While previous studies focussing on ectopic overexpression of GDF-15 have 
proposed unclear or anti-tumorigenic effects of GDF-15 in glioma cells, we here show that 
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GDF-15 at endogenous levels contributes to proliferation and immune escape of malignant 
gliomas in an immunocompetent host. 
 
 
Abbreviations: DMEM, Dulbecco’s Modified Eagle’s Medium; ECL, enhanced 
chemiluminescence; ELISA, enzyme-linked immunosorbent assay; FCS, fetal calf serum; 
GDF-15, growth and differentiation factor-15; HRP, horseradish peroxidase; MACS, 
magnetic-activated cell sorting ; TGF-β, transforming growth factor-β. 
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INTRODUCTION 
 
Human glioblastomas are characterized by a very poor prognosis. Despite multimodal 
therapy, median survival is limited to less than 5 months in population-based studies (1). The 
dismal prognosis results from the infiltrative growth of chemoresistant glioma cells in the 
brain parenchyma. Thus, there is an urgent need for new therapeutic strategies. Harnessing 
the exquisite specificity and potent cytotoxicity of immune effector cells for tumor therapy 
should be a safe and potentially powerful strategy against cancer (2). A molecular basis for 
this approach is provided by our finding that glioblastoma cells express ligands which 
activate natural killer (NK) cells and provide co-stimulation for T cells (3). However, we and 
others have also identified a number of negative immune regulatory, glioma-derived factors 
that seem to dominate tumor-host interactions in vivo. These mediators of immune tolerance 
include the non-classical MHC molecules HLA-G and HLA-E (4-5), RTF, LLT-1 (6-7), IL-
10 (8) and, most notably, TGF-β (9-10). Considering the overwhelming evidence that TGF-β 
substantially contributes to the deficits in cellular immunoreactivity displayed by human 
glioma patients, it is surprising that the potential immune-modulatory role of non-classical 
TGF-β superfamily members has so far hardly been investigated. 
In this context, we have now analyzed the expression and potential function of growth and 
differentiation factor (GDF)-15 (11) in human and murine glioma cells. GDF-15 (alternative 
names: macrophage inhibitory cytokine 1 (MIC-1) (12), placental TGF-β (PTGF-β) (13), 
placental bone morphogenetic protein (PLAB) (14), prostate-derived factor (PDF) (15), non-
steroidal anti-inflammatory drug-activated gene (NAG-1) (16), PL74 (17)), is a divergent 
member of the TGF-β superfamily which displays similarity with both bone morphogenetic 
proteins (31-35% homology) and classical TGF-β isoforms (~25% homology). It is 
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synthesized as pro-protein (279 amino acids) which is secreted and proteolytically processed 
to yield the mature homo-dimeric cytokine (2x112 amino acids). Intriguingly, the cleaved 
pro-domain can bind to the extracellular matrix (18). Thus, both the pro-domain and the 
mature protein could exert biological functions. 
Under physiological conditions, low to moderate levels of GDF-15 are expressed in most 
healthy tissues including brain (11, 19), liver, breast, colon (20) and bone marrow. However, 
much higher levels of GDF-15 are found in placenta (21) where it may help to prevent 
miscarriage (22). Additionally, GDF-15 overexpression has been described in numerous 
malignancies including breast, colorectal, pancreatic and prostate cancer (23-24). In 
melanoma, higher GDF-15 expression is seen in metastasis tissue than in primary tumor (25). 
Likewise, glioma patients with high CSF GDF-15 levels show shorter survival (26).   
Functionally, GDF-15 may exert very heterogeneous functions in tumours. It protects 
prostate cancer cells against the cytotoxic effects of docetaxel and mitoxantrone (27). 
However, it can also act as a downstream mediator of apoptosis (28). A tumor suppressor 
function of GDF-15 became evident when C57BL/6J-Apc-/+ mice were crossbred with mice 
that expressed a GDF-15 transgene. In this spontaneous model for intestinal neoplasia, GDF-
15 overexpression reduced the formation of adenomas and polyps by about 60% (29). 
Likewise, in a nude mouse glioma model, GDF-15-transfected LN-Z308 cells lost their 
tumorigenicity (30). In contrast, GDF-15-overexpressing DU145 prostate cancer cells grew 
normally in nude mice. Interestingly, the high levels of GDF-15 were linked to tumor-related 
cachexia in these animals which correlates with clinical data from prostate cancer patients 
(31). Thus, the effect of GDF-15 on tumor growth seems to depend on the tumor stage and 
type. One major problem with respect to the cited studies is that they all investigate effects 
caused by artificial overexpression of GDF-15 which may not be observed at endogenous 
GDF-15 levels. Moreover, the potential impact of GDF-15 on anti-tumor immunity has not 
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been addressed so far. Thus, we set out to investigate whether endogenous GDF-15 levels 
affect glioma growth in vitro and in vivo in the presence of a fully functional murine immune 
system. 
MATERIALS AND METHODS 
 
Cells and reagents 
All human glioma cell lines were kindly provided by Dr. N. de Tribolet (Lausanne, 
Switzerland) and have been characterized previously (32-33). Primary glioblastoma cells 
were established from freshly resected tumor tissue, cultured in monolayers and used 
between passages 4 and 9. SMA-560 glioma cells were obtained from D. D. Bigner (Duke 
University Medical Center, Durham, NC, USA). The cells were maintained in DMEM 
containing 10% FCS (Biochrom KG, Berlin, Germany) and penicillin (100 
IU/ml)/streptomycin (100 µg/ml) (Gibco, Karlsruhe, Germany). The pSUPERpuro constructs 
targeting nucleotides 722 – 740 of murine GDF-15 NM_011819.1 were cloned as previously 
described (33). For the generation of stable shGDF-15 transfectants, pSUPERpuro control or 
shGDF-15 plasmids were introduced using FuGene6 transfection reagent (Roche, Mannheim, 
Germany). The cells were selected in medium containing 2 µg/ml puromycin (Sigma, 
Deisenhofen, Germany). Anti-GDF-15 antibody was prepared as described (12, 34). 
 
Quantitative RT-PCR 
Total RNA was prepared using the RNeasy system (Quiagen, Hilden, Germany) and 
transcribed according to standard protocols. For real-time PCR, cDNA amplification was 
monitored using SYBRGreen chemistry on the ABI PRISM 7000 Sequence Detection 
System (Applied Biosystems, Weiterstadt, Germany). The conditions for these PCR reactions 
were: 40 cycles, 95°C/15 s, 60°C/1 min, using the following specific primers: 18S up: 5´-
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CGGCTACCACATCCAAGGAA-3´ (nucleotides 450-469), 18S down: 5´-
GCTGGAATTACCGCGGCT-3´ (nucleotides 636-619); GDF-15 up: 5´- 
CCCTGCAGTCCGGATACTC-3´ (nucleotides 274-292), GDF-15 down: 5´- 
GAACAGAGCCCGGTGAAG-3´ (nucleotides 400-383). Data analysis was done using the 
ΔΔCT method for relative quantification. Threshold cycles (CT) for 18S rRNA (reference) 
and GDF-15 (sample) were determined in duplicates. We chose normal brain cDNA as 
calibrator tissue (100%) and determined the relative change (rI) in copy numbers according 
to the formula rI = 2 – [(CTGDF-15 normal brain - CT18S normal brain) – (CTGDF-15 glioma - CT18S glioma)]. 
 
Immunoblot 
Supernatants were obtained from cells grown under serum-free conditions for 48 h. Soluble 
proteins > 3 kDa were concentrated using Vivaspin 20 columns (Vivascience, Hannover, 
Germany) before 20 µg/lane were separated on 15% acrylamide gels (Biorad, Munich, 
Germany). After transfer to nitrocellulose (Biorad), the blots were blocked in PBS containing 
5% skim milk and 0.05% Tween 20 and incubated overnight at 4°C with sheep anti-human 
MIC-1/GDF-15 antibody 233B3 (1:4,000) (12) which also recognizes the murine homologue. 
Visualization of protein bands was accomplished using HRP-coupled secondary antibodies 
(Sigma) and ECL (Amersham, Braunschweig, Germany). After scanning, relative signal 
intensities were quantified with Photoshop CS (Adobe, San José, CA, USA). 
 
Immunohistochemistry 
Gliomas of different WHO grade of malignancy were examined. Normal human brain white 
matter was used as control tissue, human placenta served as a positive control. GDF-15 
immunohistochemistry was performed on formalin-fixed and paraffin-embedded samples. 
Research. 
on March 14, 2014. © 2010 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 9, 2010; DOI: 10.1158/1078-0432.CCR-10-0705 
 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.  
Copyright © 2010  American Association for Cancer Research 
 
 
9
The polyclonal rabbit anti-human GDF-15 antibody was validated by the Swedish Atlas 
consortium and obtained via Sigma (#HPA011191).  
Specimens were deparaffinized first in xylol followed by decreasing concentrations of 
ethanol before antigens were retrieved by microwave boiling in 10 mM citrate buffer (pH6) 
for 10 min. Endogenous peroxidases were blocked with 3% H2O2 in methanol for 10 min. To 
prevent unspecific binding, the sections were blocked for 15 min with beriglobin. A 1:50 
dilution of anti-GDF-15 antibody in “antibody diluent” (DAKO, Hamburg, Germany) was 
applied over night at 4°C. The sections were then incubated with the biotinylated secondary 
goat anti-rabbit antibody for 15 min followed by a horseradish peroxidase-conjugated 
streptavidin incubation (both “ready to use” from DAKO) for another 15 min. Specificity 
was controlled by omission of primary antibody.   
For visualization, the sections were incubated with diaminobenzidine (DAB) (DCS 
ChromoLine, Hamburg, Germany) in DAB substrate buffer (1:25 dilution) for 5 min, before 
they were washed and counterstained with haematoxylin, followed by a graded ethanol 
series. Finally, mounting was performed in Vitro-Clud® (R. Langenbrinck, Teningen, 
Germany).  
 
ELISA 
Sera of patients without prior exposure to chemotherapy or steroids and healthy control 
donors were obtained after informed consent. All diagnoses were confirmed by histology. 
For ELISA, MaxiSorp plates (Nunc, Wiesbaden, Germany) were coated overnight with 2 
µg/ml of capture antibody (R&D Systems, #841832, Minneapolis, MN, USA) before the 
plates were washed and blocked. The pure or diluted samples were applied for 2 h at room 
temperature and bound GDF-15 was detected with biotinylated anti-GDF-15 detection 
antibody (R&D Systems, #841833) followed by streptavidin-HRP (R&D Systems) and 
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3,3'5,5'-Tetramethylbenzidin (DAKO). The colour reaction was stopped by addition of 1M 
H2SO4 and absorbance was recorded in an ELISA reader (Tecan, Männedorf, Switzerland) at 
450 nm. Using recombinant human GDF-15 as standard (R&D Systems), the assay was 
linear for GDF-15 concentrations between 0.1 ng/ml and 4 ng/ml.  
For all other cytokine measurements, freshly isolated splenocytes (5 x 106) from VM/Dk 
mice were stimulated with SMA-560 control or shGDF-15 cells (5 x 105) for 3 days in 6 cm 
dishes. Supernatants were harvested and IL-2, IL-10 and IFN-γ concentrations were 
determined by ELISA according to the manufacturer’s protocol (eBioscience, San Diego, 
CA, USA). 
 
Glioma cell proliferation 
5 x 103 SMA-560 control or shGDF-15 cells were plated in 96-well flat-bottomed plates and 
cultured in serum-free medium. Cultures were pulsed with [methyl-3H]thymidine (1 µCi; 
Amersham) on day 2 and collected 16 h later using a cell harvester (Tomtec, Hamden, CT). 
Incorporated radioactivity was bound to a glass fibre filtermat (Wallac, Turku, Finland). The 
filtermat was wetted with Ultima Gold Scintillation Cocktail (Packard, Dreieich, Germany) 
and radioactivity was determined in a Wallac 1450 Microbeta Plus Liquid Scintillation 
Counter. 
 
Preparation of murine splenocytes and NK cells 
Splenocytes were prepared from VM/Dk mice. Murine NK cells were positively selected 
using DX5 mAb-coupled magnetic beads with the corresponding column system (Miltenyi 
Biotech, Bergisch Gladbach, Germany). Polyclonal mouse NK cells were cultured with 
mouse IL-2 (5000 U/ml; PeproTech, Hamburg, Germany) for at least 10 days before being 
used as effector cells in cytotoxicity assays. 
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Lysis assays 
NK cell cytotoxicity was assessed in 4 h 51Cr release assays with 104 51[CrO4]2--labeled 
targets per well and various effector:target (E:T) ratios in 100 µl of medium. Spontaneous 
51Cr release was determined by incubating the target cells with medium alone. To obtain the 
maximum 51Cr release, NP-40 (2%) was added. After coincubation for 4 h, 50 µl of the 
supernatant were transferred to a Luma-Plate 96 (Packard, Dreieich, Germany), dried and 
measured. The percentage of 51Cr release was calculated as follows: 100 x ([experimental 
release – spontaneous release]/[maximum release – spontaneous release]). The lytic activity 
of NK cell-depleted splenocytes was examined after 5 days of coculture with glioma cells. 
Irradiated glioma cells (5 x 105) were seeded into 6 cm dishes. Splenocytes (5 x 106) were 
added in 3 ml RPMI 1640 containing 10% FCS. Primed alloreactive splenocytes were 
removed at day 5 and used at different E:T ratios in a 51Cr release assay as described above. 
 
Mice and animal experiments 
VM/Dk mice are bred in our own laboratory. Mice of 6–12 weeks of age were used in all 
experiments. The experiments were performed according to NIH guidelines, Guide for the 
Care and Use of Laboratory Animals. Groups of 6 mice were injected subcutaneously in the 
right flank with 106 transfected SMA-560 tumor cells in 0.1 ml PBS as indicated. Mice were 
examined regularly over 30 days for tumor growth using a metric caliper. Before all 
intracranial procedures mice were anesthetized by an intraperitoneal injection of 7% chloral 
hydrate. For intracranial implantation the mice were placed in a stereotactic fixation device 
(Stoelting, Wood Dale, IL, USA) and a burr hole was drilled in the skull 2 mm lateral to the 
bregma. The needle of a Hamilton syringe (Hamilton, Darmstadt, Germany) was introduced 
to a depth of 3 mm. SMA-560 glioma cells (5x103) were injected in a volume of 2 µl PBS 
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into the right striatum. The mice were observed daily and sacrificed when developing 
neurological symptoms. For immunohistochemical stainings, brain cryosections were 
prepared from mice sacrificed on day 15 after glioma cell inoculation. The following 
antibodies were used: anti-CD3 (BD Bioscience, Heidelberg, Germany), anti-CD11b (BD 
Bioscience) and anti-Ly49G2 (eBioscience). Subsequently, the slices were stained with 
secondary antibody and developed with DAB (Vectastain, Vector Laboratories, Burlingame, 
CA, USA).  
 
Statistics 
Where indicated, analysis of significance was performed using the two-tailed Student’s t-test 
(*p<0.05; **p<0.01). All experiments were performed at least 3 times and representative 
experiments are shown. 
Research. 
on March 14, 2014. © 2010 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 9, 2010; DOI: 10.1158/1078-0432.CCR-10-0705 
 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.  
Copyright © 2010  American Association for Cancer Research 
 
 
13
RESULTS 
 
GDF-15 expression in malignant gliomas in vivo translates into elevated serum levels. 
To examine the expression of GDF-15 in vivo, placenta and gliomas of different WHO 
grades were stained by immunohistochemistry (Fig. 1A). In normal human white matter 
tissue specimens (upper right), GDF-15 was detected on endothelial cells of small capillaries 
(arrow) but not on neuroepithelial cells. Diffuse astrocytomas (WHO grade II, middle left) 
and anaplastic astrocytomas (WHO grade III, middle right) showed an upregulation of GDF-
15 on neoplastic glial cells beside the endothelial expression (arrows). Strongest GDF-15 
expression was observed in glioblastomas (WHO grade IV, lower left and right) both on 
neoplastic astrocytic cells and endothelial cells of vascular proliferations (asterisk). The 
distribution of GDF-15 was homogeneous within the five samples stained for each tumor 
entity. 
We next aimed at testing whether glioma-derived GDF-15 was also detectable in the blood. 
To this end, we compared the GDF-15 levels in the sera of glioblastoma patients (n=13) and 
healthy controls (n=20). In order to avoid confounding effects of therapy-induced elevations 
of GDF-15, only samples from treatment-naïve patients, that is, without prior radiation- and 
chemotherapy and without exposure to steroids, were measured by ELISA. This revealed a 
highly significant elevation of serum GDF-15 levels in the serum of glioblastoma patients 
(p<0.01, unpaired two-sided Student´s t-test) (Fig. 1B). 
 
Human malignant glioma cells express GDF-15 in vitro. 
We went on to define the expression of GDF-15 in a panel of human glioma cell lines and 
primary polyclonal glioblastoma cell cultures in vitro. Real-time PCR revealed that GDF-15 
mRNA expression levels were 10 to 600-fold increased in all of 12 examined glioma cell 
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lines and 3 primary glioblastoma cell cultures when compared with normal human brain (Fig. 
2A). Immunoblot analysis confirmed the presence of fully processed GDF-15 in 11 of 12 
investigated glioma cell supernatants (Fig. 2B). There was a reasonably good correlation of 
mRNA and protein levels (R2=0.69) with LN-428 and A172 showing the highest GDF-15 
expression on both mRNA and protein level while the low mRNA expression found in 
U87MG, U251MG and U373MG translated into weak, but still detectable protein levels. The 
apparent lack of GDF-15 in supernatant from U138MG cells might be due to poor 
processing, inadequate secretion or to non-specific adhesion of the cytokine to the cell 
surface (35). In line with previous studies (30), no correlation (R2=0.05) was found between 
GDF-15 expression and p53 status of the cell lines (33).  
 
GDF-15 promotes glioma cell proliferation and protects malignant glioma cells from 
NK and T cell-mediated cytotoxicity in vitro  
To allow for studies in a syngeneic setting, we confirmed the expression of GDF-15 in 
supernatant of murine SMA-560 glioma cells. In order to perform loss-of-function 
experiments, we used RNA interference to stably silence the GDF-15 gene in these cells. 
Immunoblot revealed a down-regulation of GDF-15 in SMA-560_shGDF-15 pool 
transfectants by more than 90% as quantified by densitometry (Fig. 3A). Under normal cell 
culture conditions, this had no apparent effect on growth or morphology of the cells. 
However, when we investigated the proliferation  of these glioma cell sublines under serum-
free conditions, SMA-560_shGDF-15 cells incorporated significantly less [methyl-
3H]thymidine than the corresponding control-transfected cells. This effect could be reverted 
by addition of exogenous GDF-15 (5 ng/ml) or FCS (10%) to the GDF-15-depleted cells 
(Fig. 3B and data not shown) whereas addition of GDF-15 to control-transfected cells did not 
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further promote their growth. Thus, endogenously produced GDF-15 acts as an autocrine 
growth factor for glioma cells.  
One of the most striking alterations caused by depletion of TGF-β in glioma cells is the 
increase in tumor cell immunogenicity (10). Therefore, we hypothesized that GDF-15 might 
also contribute to glioma-derived immunosuppression. Using syngeneic NK cells, we found 
that SMA-560_shGDF-15 cells were significantly more susceptible to immune cell lysis than 
control cells (Fig. 3C). In order to investigate the effect of GDF-15 on immune cells other 
than NK cells, splenocytes were prepared from syngeneic VM/Dk mice and NK cells were 
depleted by MACS. The cells were cocultured for 5 days with SMA-560_control or shGDF-
15 cells and then used as effectors against fresh SMA-560_shGDF-15 targets. SMA-
560_shGDF-15 cells were efficiently killed by splenocytes primed with GDF-15-deficient 
glioma cells whereas priming with SMA-560_control cells induced significantly lower lytic 
activity (Fig. 3D). Of note, primed lymphocytes do not display cytotoxic activity against 
syngeneic splenocytes (lymphoblasts) under these conditions.  Consistent with an increase of 
the lytic activity of immune effector cells, splenocytes cocultured with SMA-560_shGDF-15 
cells generated higher levels of IL-2 and decreased IL-10 levels compared to splenocytes 
cocultured with wild-type cells (p<0.01) (Fig. 3E). In contrast, there was no difference in 
IFN-γ levels (data not shown). Control measurements without splenocytes confirmed that 
supernatant from glioma cells without splenocytes contained only negligible quantities of the 
respective cytokines: while IL-2 levels were below the detection limit, IL-10 concentrations 
were 16 pg/ml for control and 28 pg/ml for shGDF-15 cells. 
 
RNA interference-mediated GDF-15 depletion delays the growth of experimental 
gliomas in syngeneic mice 
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Taken together, the effects of GDF-15 on glioma cell proliferation and immune escape 
strongly suggest that endogenous GDF-15 expression might promote the tumorigenicity of 
glioma cells. Thus, we assessed the effect of GDF-15 depletion in vivo, using the syngeneic 
SMA-560 VM/Dk mouse model. In line with the in vitro data, tumor growth was 
significantly delayed when GDF-15–depleted rather than control-transfected glioma cells 
were subcutaneously inoculated in the flank (Fig. 4A; p<0.05 from day 10, p<0.01 from day 
22 until the end of the experiment). Likewise, when SMA-560 cells were implanted 
stereotactically into the brains of VM/Dk mice, neurological symptoms were first observed in 
animals carrying control cells. Accordingly, the median survival was prolonged from 19 days 
with control tumors to 24 days with shGDF-15 tumors (p<0.01 by two-sided, unpaired 
Student´s t-test). Thus, while at day 21 none of the animals with a control tumor was still 
alive, 83% of the mice with shGDF-15 tumors were still viable (Fig. 4B). Two mice per 
group were sacrificed during the experiment for histological analyses. Compared to mice 
with SMA560 control tumours, experimental gliomas derived from shGDF-15 cells 
displayed an increased infiltration with T cells and macrophages (Fig. 4C). In contrast, 
numbers of infiltrating NK cells were very low under both conditions (data not shown).  
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DISCUSSION 
 
The hallmarks of malignant glioma cells include their ability to deeply penetrate the 
surrounding healthy tissue and to inhibit anti-tumor immune responses. Together with their 
resistance to radio- and chemotherapy, these properties translate into a devastating tumor 
growth and a dismal prognosis. In order to gain a better understanding of the molecular 
mechanisms leading to the malignant phenotype of these cells, we characterized the role of 
GDF-15 for proliferation and immune escape of glioma cells. Immunohistochemistry 
confirmed that the majority of gliomas express GDF-15 in vivo (Fig. 1). Compared to 
gliomas of WHO grades II and III, we noticed an increase of GDF-15 expression and more 
GDF-15 positive cells in WHO grade IV tumors. These findings apparently contradict the 
observation from Shnaper et al. (26) who found glioblastoma cells to be GDF-15 negative in 
vivo. However, the polyclonal rabbit serum provided by the Atlas consortium may be the first 
GDF-15 antibody to give reliable results in immunohistochemistry. Considering that 
previous studies have also detected GDF-15 mRNA (36) and protein (37) in gliomas, we 
trust in the validity of our data. These immunohistochemical observations are further 
supported by GDF-15 expression analyses in established glioma cell lines. As demonstrated 
in Fig. 2A, GDF-15 transcripts were upregulated in all of 12 permanent glioma cell lines and 
three primary polyclonal glioblastoma cell cultures compared to normal human brain. 
Further, GDF-15 protein was also detectable in the supernantant of most investigated glioma 
cell lines where its expression largely paralleled the mRNA data. Slight alterations might be 
due to posttranscriptional regulation and differences in secretion of the protein in different 
cell lines (35). In summary, our results clearly demonstrate that glioma cells express GDF-
15. Nevertheless, tumor-associated microglial cells might also make a substantial 
contribution to the total GDF-15 levels observed in glioma patients, as proposed by others 
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(26). A second important finding from our study which had not been observed in a previous 
publication were the increased serum GDF-15 levels of glioblastoma patients (Fig. 1B). The 
very clear (p<0.01) difference noticed in our study might be due to the fact that we 
exclusively included treatment-naïve patients thereby avoiding any confounding effects by 
steroids, chemotherapeutics or irradiation. 
In order to define the functional role of glioma-derived GDF-15, we silenced GDF-15 
expression in murine SMA-560 glioma cells by RNA interference. This allowed for 
immunological studies and a functional characterization of GDF-15 in a syngeneic setting 
(Fig. 3A). We noticed a reduced proliferation of glioma cells that were depleted of GDF-15 
(Fig. 3B). However, this effect was not only reverted by addition of recombinant GDF-15 but 
also by FCS indicating that in complete medium, the lack of GDF-15 is counterbalanced by a 
multitude of growth factors. In contrast, our immunological studies clearly point out for a 
novel and until now unrecognized role of GDF-15 as a glioma-derived immunosuppressive 
molecule. As demonstrated in Fig. 3C, glioma cells depleted of GDF-15 are more susceptible 
to the lytic activity of NK cells. Likewise, splenocytes from syngeneic mice display 
improved cytotoxic capacity against SMA-560 targets when primed with shGDF-15 cells 
rather than with SMA-560 control transfectants. This improved immune cell activation in the 
absence of GDF-15 is further corroborated by an increase in lymphocyte-derived IL-2 and a 
decrease in IL-10 in coculture studies (Fig. 3E). These data demonstrate that anti-GDF-15 
strategies may partly relieve glioma-induced immunosuppression and enable effective 
antitumor responses in vitro. 
In syngeneic mice, subcutaneously injected SMA-560 control cells grew faster than SMA-
560 shGDF15 transfectants (Fig 4A). In line with these findings, we observed a survival 
advantage for mice that had intracranial tumors derived from shGDF-15 cells (Fig. 4B). 
These findings are in contrast to an earlier publication which described that GDF-15-
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transfected LNZ-308 glioma cells lost tumorigenicity in nude mice (30). However, this 
model is not only unsuitable for the detection of immunological tumor-host interactions. 
Ectopic overexpression of GDF-15 may further lead to unphysiologically high cytokine 
levels that could affect angiogenesis (38). Thus, down-modulation of endogenously 
expressed GDF-15 in an immune-competent orthotopic mouse model (as described here) is 
likely to reflect the actual role of GDF-15 in glioma more accurately. Further evidence for 
the presumed immunomodulatory role of GDF-15 comes from the observation that GDF-15 
depleted tumors show stronger infiltration with T cells and macrophages (Fig. 4C). This 
might, however, be a double-edged sword, since infiltration with regulatory T cells (39) or 
the presence of tumor-associated macrophages (40) have been linked to a poor outcome in 
other tumor entities. In brain tumors, however, the presence of Treg appears to be 
prognostically neutral within the entity of glioblastomas (41). Likewise, no correlation was 
found between the total number of tumor-infiltrating macrophages and prognosis (42) 
whereas a (rarely observed) severe lymphocytic infiltration was linked to a significantly 
longer survival (43). The magnitude of T-cell infiltration may be inversely proportional to 
intratumoral TGF-β2 levels and correlates positively with clinical outcome (44) – which 
bears some resemblance to our in vivo data on the divergent TGF-β superfamily member 
GDF-15. The fact that even mice with GDF-15-depleted tumors died suggests that the lack of 
GDF-15 might have been compensated by other immune-inhibitory mechanisms such as 
TGF-β. In addition, a selection process for glioma cell clones with a less substantial knock-
down of GDF-15 expression might have occurred. Unfortunately, due to a lack of adequate 
reagents this hypothesis cannot currently be tested by immunhistochemical analysis of mouse 
tumors. Finally, GDF-15 may also have been provided by host cells, e.g. by microglia in the 
tumor microenvironment. However, the current lack of knowledge regarding the GDF-15 
receptor and its associated signaling mediators do not only limit the mechanistic 
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understanding of the involved processes. They also preclude experimental pharmacological 
approaches like the inhibition of signaling at the receptor level or the specific blockade of 
GDF-15 dependent signaling cascades. Nevertheless, the reasonably mild phenotype 
displayed by GDF-15 knock-out mice (45) suggests that such strategies might be more safely 
directed towards GDF-15 than towards TGF-β, where the targeting of receptor kinases (46) 
has given rise to serious concerns regarding the safety of this approach. Overall, our study 
clearly demonstrates that GDF-15 confers immune privilege to malignant gliomas, 
contributes to the malignant phenotype of these cells and thus represents a novel and 
promising target for future therapies. 
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Figure legends 
 
Fig. 1. Human malignant gliomas express GDF-15 in vivo. 
A. Paraffin-embedded tissue sections of normal human white matter (upper right), diffuse 
astrocytomas (WHO grade II, middle left), anaplastic astrocytomas (WHO grade III, middle 
right) and glioblastomas (WHO grade IV, lower left and right) were assessed by 
immunohistochemistry. Normal human placenta (upper left) served as positive control. 
Syncytiotrophoblasts and endothelial cells which are both expected to express GDF-15 are 
indicated by arrowheads and arrows, respectively. Five specimens from each entity were 
stained. Representative stainings are shown (original magnification 200x for all 
photomicrographs). B. GDF-15 levels in sera of treatment-naïve glioblastoma patients (n=13) 
and healthy controls (n=20) were determined by ELISA. Median values are indicated. (** 
denotes p<0.01 as assessed by two-sided, unpaired Student´s t-test). 
 
Fig. 2. Malignant glioma cells express GDF-15 in vitro. 
A. GDF-15 expression was analysed by real-time RT-PCR using 18S RNA as a reference, 
with quantitative data expressed relative to normal brain cDNA. B. GDF-15 levels in cell 
culture supernatants (20 µg/lane) were assessed by immunoblot. 
 
Fig. 3. GDF-15-depleted glioma cells are more susceptible to immune cell-mediated 
cytotoxicity in vitro. A. Cell culture supernatants of SMA-560 control or shGDF-15 cells (20 
µg/lane) were assessed for GDF-15 protein levels by immunoblot. B. The growth rates of 
SMA-560 control or shGDF-15 cells were examined by [methyl-3H]thymidine incorporation 
for 16 h. C. Lytic activity of mouse NK cells against syngenic SMA-560 control (filled 
diamonds) or shGDF-15 (open squares) cells was assessed in a 4 h 51Cr release assay. D. 
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DX5-depleted syngeneic splenocytes were co-cultured (primed) with SMA-560 control or 
shGDF15 cells for 5 days. The lytic activity of primed splenocytes against SMA-560 shGDF-
15 cells was determined in a 4 h 51Cr release assay. E. Cytokine levels in cocultures of DX5-
depleted splenocytes with SMA-560 control or shGDF-15 glioma cells were determined by 
ELISA. 
 
Fig. 4. RNA interference targeting GDF-15 delays the growth of subcutaneous and 
intracerebral gliomas in syngeneic immunocompetent mice. A. VM/Dk mice were sub-
cutaneously injected with 105 SMA-560 control (filled squares) or shGDF-15 (open 
triangles) cells. Tumor size was measured using a caliper every 3 days. B. SMA-560 control 
or siGDF15 transfectants were inoculated intracerebrally in syngenic VM/Dk mice. Survival 
data for 6 animals per group are presented as Kaplan-Meier plot. C. At day 15 after tumor 
inoculation, 2 animals were sacrificed. Their brains were removed, shock-frozen and 
assessed for the infiltration of T cells and macrophages. Representative stainings are shown. 
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